Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: khrnyc who wrote (1952)	1/22/1998 12:57:00 PM
From: Tokyo VD	Read Replies (2) \| Respond to of 7041

Keith, You appear to be a very forthright person. I was on that conference call (I believe Tony Butler hosted it) and remember someone specifically asking you about your credentials in the area of treatment for HIV. Your reponse, if I recall correctly, was that you were not an HIV/AIDS specialist, nor did you have any academic papers published. Furthermore, if I recall correctly, you admitted you were not an expert in this field. Now, you have turned your attention to ED. You continue to cite the ED conference in Los Angeles as where you obtained your data, but once again I'm going to shoo that notion away. For others, Raymond Rosen (a psychologist who likes people to refer to him as a Dr. Ray Rosen), inventor of the IIEF questionnaire, addressed the attendees on Zonagen's behalf. Rosen is a paid consultant to Zonagen, testing their Vasomaxine (indication for women suffering from ??). In his presentation, Ray specifically discussed the half life of Vasomax/phentolamine po in the blood stream. In fact, he specifically addressed the pharmacokinetics of Vasomax/phentolamine po when he stated that "this is pretty close to the perfect pharmacokinetic profile." While I disagree with Ray, he did state this as fact. Keith, you really are going to have to go back to your employer and ask for help in this matter. Lastly, Rosen did not present the entire data at this conference. If you were really present, then you would know that he presented a substantial amount of data on the parallel designed study (40% efficacy vs. 17% placebo), but little information on the crossover study (34% efficacy vs. 21% placebo). Really, I must ask again. What on earth are you doing in this forum misleading people? Tokyo

To: khrnyc who wrote (1952)	1/22/1998 6:40:00 PM
From: Dr. Voodoo	Read Replies (1) \| Respond to of 7041

Dr. Rubin or Tokyo, After having read Poodle's literature references could you please illustrate for the Medically Challenged(myself) exactly how: 1) The drug may be affected by gastrointestinal (GI) transit time (how fast substances move through the GI tract). 2) Stomach ph can inactivate the drug. 3) The drug first goes to the liver and is metabolized and much is inactivated (the so-called "first pass" effect) Below are the references so you don't have do go back and look. In a prospective study of 15 consecutive impotent patients we evaluated the erectile responses to intracavernous injections of standardized doses of papaverine and phentolamine alone and incombination. Of the 15 patients 13 achieved a full erection with the drug combination, whereas only 6 achieved a full erection with papaverine and 1 with phentolamine. Our results suggest an effective alternative to the use of papaverine alone, whose long-term sequelae have been shown to be deleterious. REFERENCE 2 Br J Urol 1989 Jan;63(1):95-97 Effect of phentolamine on venous return in human erection. Wespes E, Rondeux C, Schulman CC A group of 25 patients underwent Doppler penile blood examination and cavernometry before and after 5 mg of phentolamine injected intracavernously. The organic or psychogenic nature of impotence was determined by psychological testing, the intracavernous injection of papaverine, hormonal evaluation, neurological examination, Doppler penile blood flow measurement and cavernometry for vascular investigations. The intracavernous injection of phentolamine had no effect on the venous return and it provoked penile arterial dilatation. The erectile angle, which was also measured, was less evident than after the injection of papaverine. The results confirmed the fact that an increase in arterial inflow alone is not sufficient to induce a rigid erection in man. Thanks in advance